Vasopressor Weaning Sequence Does Not Alter Hypotension Risk

The Vasopressor Weaning Dilemma in Septic Shock

Septic shock is characterized by profound, persistent hypotension that requires prompt initiation of vasopressors to maintain adequate organ perfusion [1, 2]. Norepinephrine remains the universally recommended first-line agent, with vasopressin frequently added as a second-line therapy for refractory cases [2, 3]. As patients stabilize and enter the recovery phase, intensive care physicians face a common clinical question regarding which of these potent medications to taper first to minimize rebound hypotension [4, 5]. Previous literature has yielded conflicting guidance, with some earlier analyses suggesting that discontinuing norepinephrine first might reduce the risk of subsequent hypotensive episodes [4]. A recent systematic review and meta-analysis evaluated the optimal weaning sequence for these critical medications, providing data to help clinicians safely de-escalate hemodynamic support [6].

Evaluating Overall Hypotension Risk

To determine the optimal strategy for de-escalating hemodynamic support, researchers conducted a systematic review and meta-analysis evaluating the incidence of hypotension when discontinuing either norepinephrine or vasopressin first. The analysis included 11 studies, comprising 2 randomized controlled trials and 9 observational studies. In total, the researchers evaluated data from 2,280 patients who required dual vasopressor therapy. Within this cohort, the investigators compared two distinct weaning sequences, noting that norepinephrine was withdrawn first in 1,254 patients, while vasopressin was withdrawn first in the remaining 1,026 patients. An initial review of the raw data revealed that hypotension occurred in 33.4% (420 of 1,254) of patients in the norepinephrine group, compared to 52.4% (538 of 1,026) of patients in the vasopressin group. However, despite this apparent numerical gap in the raw percentages, the pooled statistical analysis demonstrated that there was no overall difference between the groups regarding the incidence of hypotension (odds ratio 0.43; 95% confidence interval 0.18 to 1.03). For practicing intensivists, this indicates that across the combined body of evidence, choosing to taper norepinephrine before vasopressin does not significantly alter the overall risk of clinically relevant blood pressure drops during the recovery phase of shock.

Conflicting Data Between Trial Designs

While the overall pooled data showed no significant difference, separating the results by study design revealed sharply conflicting outcomes. A subgroup analysis of the 9 observational studies suggested a lower incidence of hypotension when norepinephrine is weaned first (odds ratio 0.26; 95% confidence interval 0.13 to 0.53). In stark contrast, the prospective data pointed in the exact opposite direction. A subgroup analysis of the 2 randomized controlled trials indicated a higher incidence of hypotension when norepinephrine is weaned first (odds ratio 4.04; 95% confidence interval 1.24 to 13.15). Interpreting this divergence requires looking at the statistical consistency within the subgroups themselves using the I-squared statistic, a measure that quantifies the percentage of variation across studies that is due to true differences rather than chance. The observational studies subgroup showed high heterogeneity (I2 = 88%; p < 0.01), meaning there was substantial variation in patient populations, clinical protocols, or outcomes among those nine cohorts. The randomized controlled trials subgroup showed heterogeneity of I2 = 65% (p = 0.09), which also indicates notable variation despite the controlled study designs. Because the data points in opposite directions depending on the trial type, the authors noted that high heterogeneity across studies warrants caution in drawing definitive conclusions about which vasopressor clinicians should discontinue first.

Secondary Outcomes and Clinical Takeaways

Beyond the primary concern of rebound hypotension, the researchers evaluated whether the choice of which vasopressor to discontinue first impacted broader clinical metrics. The analysis demonstrated that the specific weaning strategy was not associated with intensive care unit length of stay or hospital length of stay. For clinicians managing resource utilization and patient recovery timelines, it is also notable that the weaning strategy was not associated with time on vasopressors, indicating that neither sequence prolonged the overall duration of hemodynamic support. The investigators also assessed potential complications and markers of organ dysfunction related to the de-escalation process. They found that the weaning strategy was not associated with arrhythmias, a frequent concern when manipulating catecholamine infusions. Additionally, the weaning strategy was not associated with renal injury, suggesting that kidney perfusion is maintained equally well regardless of whether norepinephrine or vasopressin is tapered first. Finally, the weaning strategy was not associated with Sequential Organ Failure Assessment (SOFA) scores, a standard clinical tool used to track the severity of organ dysfunction in the intensive care unit. Because neither approach demonstrates a clear superiority in preventing hypotension or improving these secondary outcomes, practicing intensivists can safely tailor their vasopressor weaning strategy to individual patient hemodynamics rather than adhering to a rigid protocol.

References

1. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Critical Care Medicine. 2021. doi:10.1097/ccm.0000000000005337

2. Elkady G, Elshafei M, Mostafa A, Awoad ATA. Vasopressors in Septic Shock (A Systematic Review / Meta-Analysis). 2020. doi:10.1093/qjmed/hcaa039.034

3. Mamede I, Arêa L, Carvalhal G, Bessa R, Lenzi M, Santos MCFD. Early vasopressin plus norepinephrine versus delayed or no vasopressin in septic shock: A systematic review and meta-analysis.. The American journal of emergency medicine. 2026. doi:10.1016/j.ajem.2025.10.003

4. Song JU, Lee J, Park HK, Suh GY, Jeon K. Incidence of Hypotension after Discontinuation of Norepinephrine or Arginine Vasopressin in Patients with Septic Shock: a Systematic Review and Meta-Analysis.. Journal of Korean medical science. 2020. doi:10.3346/jkms.2020.35.e8

5. Hammond DA, Sacha GL, Bissell BD, et al. Effects of Norepinephrine and Vasopressin Discontinuation Order in the Recovery Phase of Septic Shock: A Systematic Review and Individual Patient Data Meta-Analysis.. Pharmacotherapy. 2019. doi:10.1002/phar.2265

6. Mallmann C, Silva LOJ, Oliveira MSD, Galiotto TMB, Nedel WL, Moraes RB. Effect of norepinephrine versus vasopressin weaning on incidence of hypotension in septic shock patients: a systematic review and meta-analysis.. Critical care science. 2026. doi:10.62675/2965-2774.20260197